Breaking News, Collaborations & Alliances

KBI Biopharma & Alanis Therapeutics Partner to Advance Cancer Therapy

Enter a manufacturing contract for the development of an innovative pre-clinical therapeutic antibody to treat MDS and AML blood cancers.

Author Image

By: Charlie Sternberg

Associate Editor

KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has entered a manufacturing contract with Alanis Therapeutics, Inc. (ATI) for the development of an innovative pre-clinical therapeutic antibody to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) blood cancers.   Under this collaborative agreement, KBI will leverage its advanced monoclonal antibody development and manufacturing platform, SUREmAb, to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters